Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

August 22, 2023

Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.

August 18, 2023

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.

August 18, 2023

Prioty Islam, MD, MSc, discusses how the FDA approval of the noncovalent BTK inhibitor pirtobrutinib has transformed the treatment of patients with mantle cell lymphoma, and where this agent fits in to the current treatment armamentarium.

August 17, 2023

Deb Schrag, MD, MPH, discusses the rationale for exploring the use of selective preoperative chemoradiation in patients with locally advanced rectal cancer, the safety and efficacy findings from the PROSPECT trial, and the importance of reviewing patient-reported outcomes during clinical trials.

August 15, 2023

Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.

August 15, 2023

Experts on HR+/HER2- breast cancer discuss biomarker testing approaches, including sampling considerations and timing of testing.

August 11, 2023

Helena A. Yu, MD, discusses the investigation of BL-B01D1 in patients with advanced solid tumors, the potential significance of this research for those with EGFR-mutant and wild-type disease, and the expanding body of evidence supporting continued antibody-drug conjugate development in non–small cell lung cancer.

August 08, 2023

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.

August 08, 2023

A focused discussion on trials that may address disease progression on first-line therapy, including those on ET and CDK4/6 inhibitor rechallenge and novel combination strategies.

August 02, 2023

Prioty Islam, MD, MSc, discusses the impact of the updated safety and efficacy data seen with FDA-approved BTK inhibitors in patients with chronic lymphocytic leukemia.

August 02, 2023

Prioty Islam, MD, MSc, reviews the benefits of using covalent BTK inhibitors in CLL and MCL; considerations for choosing first-generation vs next-generation covalent BTK inhibitors in patients with these B-cell malignancies; and the potential future role for ibrutinib in the CLL treatment paradigm.

August 01, 2023

Prioty Islam, MD, MSc, discusses findings from the BRUIN trial, highlights the potential benefits of using noncovalent BTK inhibitors instead of or before covalent BTK inhibitors in patients with MCL or CLL, and previewed ongoing clinical trials investigating this class of agents in earlier treatment lines in these populations.

August 01, 2023

Prioty Islam, MD, MSc, discusses the importance of shared decision making between patients and clinicians when selecting among available BTK inhibitors in the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.

August 01, 2023

Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.

August 01, 2023

Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.

July 28, 2023

Jan Bewersdorf, MD, discusses the design of an ongoing phase 1 trial investigating ruxolitinib plus abemaciclib in patients with primary or secondary myelofibrosis.

July 25, 2023

Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.

July 25, 2023

Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.

July 21, 2023

Lorenzo Falchi, MD, iscusses the use of glofitamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

July 21, 2023

Eileen M. O’Reilly, MD, expands on the updated survival data from NAPOLI-3, explains how NALIRIFOX could fit into the current pancreatic ductal adenocarcinoma treatment paradigm, and shares potential opportunities to build upon this research moving forward.